NCT02009488View on ClinicalTrials.gov

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2014

Primary Completion Date

January 3, 2017

Study Completion Date

January 3, 2017

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Canagliflozin, 100 mg

One 100 mg capsule taken orally (by mouth) once daily

DRUG

Canagliflozin, 300 mg

One 300 mg capsule taken orally (by mouth) once daily

DRUG

Placebo

One placebo capsule (inactive medication) once daily.

Trial Locations (2)

Unknown

San Diego, La Jolla

Gainesville

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter